Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9777	Companies
195686	Keywords
126721	Articles
104053	Press releases

Home
Companies
Biophytis

BRIEF

published on 07/07/2025 at 07:05, 6 months 23 days ago

Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis BIO101 Muscle Preservation GLP-1 Therapies Obesity Market
REGULATED PRESS RELEASE

published on 07/07/2025 at 07:00, 6 months 23 days ago

Obesity: Biophytis Charts Its Course Toward a Booming Market
Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market

BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA
BRIEF

published on 07/03/2025 at 07:05, 6 months 27 days ago

Biophytis Showcases Innovations at BIO International 2025

Biophytis Precision Medicine Longevity Sarcopenia Obesity Therapy
REGULATED PRESS RELEASE

published on 07/03/2025 at 07:00, 6 months 27 days ago

Biophythis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025
Biophytis highlights innovations in obesity, muscle health, and longevity at BIO International 2025, showcasing therapies targeting key health challenges. Strategic partnerships post-conference aim to accelerate therapies' global impact

Innovations Longevity Obesity Muscle Health Biophy(s
BRIEF

published on 06/30/2025 at 22:35, 6 months 29 days ago

Biophytis Delays Publication of 2024 Annual Financial Statements

Biophytis Biotechnology Drug Development Annual Accounts Financial Delay
REGULATED PRESS RELEASE

published on 06/30/2025 at 22:30, 6 months 29 days ago

Information on the Annual Financial Statements
Biophytis delays publishing of 2024 annual accounts, aiming for release by July 7. The company focuses on treatments for age-related diseases

Financial Statements Biophytis Age-related Diseases 2024 Annual Accounts Clinical-stage Biotechnology Company
PRESS RELEASE

published on 06/30/2025 at 22:29, 6 months 29 days ago

Information on the Annual Financial Statements
Biophytis SA delays publication of 2024 annual accounts, aiming to release by July 7. The clinical-stage biotech company focuses on age-related disease treatments

Biotechnology Company Clinical-stage Biophytis SA Age-related Diseases 2024 Annual Accounts
BRIEF

published on 06/19/2025 at 23:05, 7 months 10 days ago

Biophytis Temporarily Suspends Share Trading

Biophytis Regulatory Compliance Financial Report Euronext Growth Share Suspension
REGULATED PRESS RELEASE

published on 06/19/2025 at 23:00, 7 months 10 days ago

Biophytis announces the temporary suspension of the trading of its shares
Biophytis announces temporary suspension of trading shares on Euronext due to delayed financial report. Expected to resume after report publication. Company info included

Biophytis Euronext Trading Financial Report Suspension
PRESS RELEASE

published on 06/19/2025 at 22:59, 7 months 10 days ago

Biophytis announces the temporary suspension of the trading of its shares
Biophytis announces temporary suspension of trading of its shares by Euronext due to non-publication of annual financial report for 2024, expected to resume after report publication

Biophytis Shares Euronext Trading Suspension

Accesswire

Published on 01/30/2026 at 14:00, 7 hours 31 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 12 hours 56 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 13 hours 31 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 19 hours 16 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 21 hours 31 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 20:10, 1 hour 20 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 1 hour 21 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 1 hour 23 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 2 hours 17 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 2 hours 59 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 01/30/2026 at 17:45, 3 hours 46 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 13 hours 31 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 3 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 3 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 3 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE